Abstract
Realizing the promise of therapeutic cardiac regeneration requires the targeting of accessible cell sources to promote neomyogenesis for the injured heart. After initial trials with cardiac myocytes and skeletal muscle progenitor cells (myoblasts), the rapid advances of stem cell technology have established the feasibility of endogenous stem cells to serve as donor cells for cellular cardiomyoplasty. In particular, bone marrow-derived stem cells have a great potential for clinical application due to their extracardiac locale and capacity to give rise to functional cardiac myocytes. The recent identification of resident cardiac stem cells also offers the opportunity to regenerate the infarcted myocardium, using the cells from the heart for ex vivo expansion or as targets for in vivo induction. To this end, future advances in cellular cardiomyoplasty may likely be based on therapies stimulating the trophic/cellular interactions that direct exogenous/endogenous stem cell-mediated cardiac regeneration.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
